TABLE I.

Pre–Neoplastic Findings (In Dorsolateral Prostate) of Male Apc^Min/+ (Min) Mice (Mean ± SE Per 10 20 × Images)

Treatment group	Low grade PIN		High grade PIN			Microinvasive carcinoma
wt (control; age 6 months)	0.4 ± 0.1	**	0.0 ± 0.0	**	**	0.0 ± 0.0	** *
Min (age 6 months)	1.5 ± 0.31		1.2 ± 0.20			1.0 ± 0.21		*	*
Min (age 6 months) + anti-TNF	1.6 ± 0.30		1.1 ± 0.31			0.6 ± 0.16
Min (age 6 months) + TREG	1.7 ± 0.30		1.1 ± 0.31			0.4 ± 0.16
Min (age 3 months) untreated	1.6 ± 0.30		0.9 ± 0.34			0.2 ± 0.13
Min (age 3 months) + sham IgG	1.4 ± 0.22		0.5 ± 0.16	*		0.3 ± 0.15	*
Min (age 3 months) + anti-CD25 IgG	1.5 ± 0.30		1.6 ± 0.16			1.0 ± 0.21

Frequency and features of prostate lesions are given in this table. CD25⁺ cells are important in impeding age-related progression of neoplasia in the prostate of Min mice. Min mice depleted of CD25⁺ cells (N = 8 mice per trial) from age 1 to 3 months had significantly more HGPIN and microinvasive carcinoma prostate lesions when compared to agematched sham antibody treated (N = 8 mice per trial) control Min mice. Min mice that received supplemental CD25⁺ T_REGS (N = 5 mice) showed a statistically significant decrease in the frequency of microinvasive carcinoma lesions when compared to Min mice of matched age = 6 months (N = 5 mice). Grading of neoplastic progression in the DLP of mice and analysis of results was performed as described in Material and methods.

^*p < 0.05;

^**p < 0.01;

^***p < 0.001.